TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Internet-delivered Psychotherapy for Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* be fluent in Romanian~* be over 18 years~* have a diagnosis of current major depression disorder~* have access to an Internet connected computer~Exclusion Criteria:~* suicidal ideation~* ongoing psychological treatment for depression~* other primary disorder that need treatment~* obstacle to participation (i.e., long travel plans)~* recent change in psychiatric medication (i.e., during the last 6 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional-CBT (C-CBT) (Type: EXPERIMENTAL): This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
- Religious CBT (R-CBT) (Type: EXPERIMENTAL): This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
- Wait List Control Group (WLCG) (Type: NO_INTERVENTION): This arm represents the wait-list comparison group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, 18 years of age and older.~* Present to one of the participating hospitals.~* Have a chief complaint of one of the target diagnoses.~* Are within a certain geographical area (based on zip codes).~* Have a health insurance plan that covers ACH services.~* Have the capacity to consent or could assent with the consent of a health care proxy who is physically present.~Exclusion Criteria:~* The patient is not suitable for ACH or inpatient hospital care based on:~  * being a nursing home patient;~ * on or requiring dialysis;~ * positive for COVID-19;~ * having discharge order;~ * requiring intensive care unit (ICU) level of care;~ * history of drug abuse.~* Patients will also need to meet the clinical stability criteria.~* Do not have the capacity to consent or assent with the assistance of a health care proxy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced Care at Home (ACH) (Type: EXPERIMENTAL): Patients will receive inpatient hospitalization at home.
- Traditional Inpatient (Brick-and-Mortar) Hospital Care (Type: ACTIVE_COMPARATOR): Patients will receive inpatient hospitalization at the hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Implanted dual-chamber pacemaker or ICD system with replacement indication~  * Because of battery end of life~ * Because of upgrade from pacemaker to ICD system~    * predominant sinus rhythm (paroxysmal atrial fibrillation \[AF\] \< 2 hours/day)~   * predominant ventricular stimulation (\>= 80%)~   * NYHA Class II-III~   * LVEF \<= 35%~Exclusion Criteria:~* NYHA Class IV~* Life expectancy of less than one year because of accompanying diseases~* Myocardial infarction less than 3 months old~* Cardiac surgery less than 3 months~  * Bypass~ * Valve surgery~ * Percutaneous transluminal coronary angioplasty (PTCA)~* Thoracotomy, for implant of an epicardial LV electrode~* Medical circumstances that make participation and compliance impossible~* Patients who are not willing or able to give written consent for their study participation~* Participation in another study~* Patients less than 18 years old~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BiV Pacing (Type: EXPERIMENTAL): Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
- RV Stimulation (Type: ACTIVE_COMPARATOR): Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinician Assessment of Patient Dyspnea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects 18 years and older,~* Admitted to RUMC~* Non-intubated,~* Admitted with a diagnosis of heart failure (HF), chronic obstructive pulmonary disease (COPD), asthma, pneumonia, a generic diagnosis of shortness of breath, or requiring supplemental oxygen support.~Exclusion Criteria:~* Less than 18 years old,~* Non-English-speaking,~* Subjects unable to answer questions about dyspnea for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women aged 18-45 who are within 3 months of delivering a healthy, term (37 to 40 weeks) singleton~* diagnosis of bipolar postpartum depression - depressed with peripartum onset~* have a 17-item Hamilton Rating Scale for Depression score of \>18~* have failed to respond to an adequate trial of the mood stabilizer~* are currently not on any psychotropic drug except a mood stabilizer (lithium, lamotrigine or quetiapine)~* are able to communicate (written and oral) in English and capable of giving consent~Exclusion Criteria:~* current major depressive episode of more than 6 months duration~* a current comorbid psychiatric disorder~* history of alcohol or substance abuse within the 12 months before screening~* concurrent psychotherapy~* high risk for suicide (actively suicidal or a score of = 3 on item #3 on HAM-D)~* current hepatic, renal, or cardiac disease, chronic pain, coagulation disorders, esophageal or gastro duodenal ulceration within the previous 30 days~* known immediate-type hypersensitivity to COX-2 inhibitors, sulfonamides, ibuprofen, or diclofenac~* breastfeeding mothers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Adjunct celecoxib in 6 week treatment
- Placebo (Type: PLACEBO_COMPARATOR): Adjunct placebo in 6 week treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LESCOD: Lewy Body Screening in Cognitive Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be a woman or a male \>60 to \< 90 years~* Have sufficient visual and auditory acuity~* Be able to speak, read, hear and understand french language~* Be covered by health care insurance~* Have a reliable help/partner/informant/caregiver~* Have a mild to severe cognitive decline based on MMSE (Mini-Mental State Examination) score ( From 18 to 26)~* Give oral agreement to the assessment of the LEsCoD scale during routine consultation~* Have performed neuropsychology tests and MRI respectively within 6 and 12 months~Exclusion Criteria:~* Has evidence of neurological or psychiatric disorder other than AD or DLB explaining cognitive decline~* Has received previously or currently neuroleptic treatment~* Has no reliable help/caregiver the day of the visit~* Refuses to give his/her oral agreement to the assessment of the LeSCoD scale~* Has presence on MRI of radiologic evidence of cerebrovascular disease (score Fazekas 2)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Alzheimer disease (AD) (Type: OTHER): Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
- Dementia with Lewy Bodies (DLB) (Type: OTHER): Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
- Probable AD and possible DLB (Type: OTHER): Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers and patients with type 2 diabetes~* Non-smoking, Caucasian and African American, male and female (postmenopausal, surgically sterile or using double-barrier method of contraception) subjects between 30 and 65 years of age (inclusive)~* Type 2 diabetics on metformin and/or sufonylurea~Exclusion Criteria:~* History of type 1 diabetes or insulin use~* History of coagulation abnormalities~* History of abnormal heart conditions~* Pregnancy or breastfeeding~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Healthy volunteers
- 2 (Type: EXPERIMENTAL): Type II diabetics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 12-18.~* Patient scheduled for elective tonsillectomy +/- adenoidec-tomy, +/- BMTs.~* ASA physical status I and II.~Exclusion Criteria:~* Severe upper respiratory tract infections.~* Patients who are actively on gabapentin or pregabalin, pre-existing with pain syndromes, chronic use of opioids, allergy to gabapentin, acetaminophen, and or NSAIDs~* Patient who lacks of fluency in English or inability to communicate pain.~* Patient who has severe asthma, bleeding disorders, and history of gastrointestinal bleeding, epilepsy, renal impairment or any other medical problem that in the opinion of the investigator would interfere with study population.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Gabapentin (Type: EXPERIMENTAL): Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
- Hydrocodone (Type: ACTIVE_COMPARATOR): Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study on Diurnal Variation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~PKU PARTICIPANTS (ARM 1):~* Subject has a confirmed diagnosis of PKU with hyperphenylalaninemia documented by a fasting Phenylalanine level of at least 360 umol/L (6 mg/dL)~* Patient is at least 4 years old (there is no upper age limit for this study)~* Willing and able to provide written authorization or, if under the age of 18 years, provide written assent (if required) and written patient authorization by a parent or legal guardian~* Willing to undergo study related procedures including commencing Kuvan treatment for patient not currently on treatment; temporary discontinuation of Kuvan for patient on treatment; and completing the 24-Hour Blood Assessment~* Authorized to provide personal health information~* Subjects should not be pregnant and willing to use appropriate birth control during the study~CONTROL GROUP (ARM 2):~* Healthy, non-PKU individuals. They will be age-sex matched to the PKU group. They may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~* Individual is at least 4 years old (there is no upper age limit)~* Willing and able to provide written consent or, if under the age of 18 years, provide written assent and written participant authorization by a parent or legal guardian~* Authorized to provide personal health information~Exclusion Criteria (BOTH ARMS):~* Subjects who do not meet all the inclusion criteria~* Age \< 4 years~* Concomitant medical problems or medications which at the discretion of the principal investigator would put participant at health risk or prevent them from completing study.~* If female, unwillingness to use birth control during the period of the study drug administration (this doesn't apply to Arm 2)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PKU Participants (Arm 1) (Type: EXPERIMENTAL): * Subjects will be administered Kuvan once daily.~* They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6).
- Control Group (Arm 2) (Type: NO_INTERVENTION): * Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~* These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (ages 18 years or older) with diabetes mellitus~* Best corrected visual acuity worse than 20/40 but no worse than 20/800 in the study eye~* Best corrected visual acuity better than or equal to 20/800 in the fellow eye~* DME in the study eye (eye scheduled to undergo cataract surgery) as documented on OCT as a center point thickness of at least 250 microns no more than 3 weeks prior to cataract surgery~* No prior laser photocoagulation in the study eye for at least 4 months prior to cataract surgery~* Women of child-bearing potential who are interested in participating in this study will use two effective forms of contraception prior to initiation of pegaptanib and then throughout the remainder of the study. For women of childbearing potential, results from a urine pregnancy test will be obtained prior to each injection with pegaptanib. Urine samples will be disposed of after the test is performed.~Exclusion Criteria:~* History of intravitreal steroid (triamcinolone) injection into the study eye within 4 months prior to cataract surgery~* Macular edema due to non-diabetic etiologies such as vein occlusion~* Retinal diseases that preclude evaluation of the macula for edema (e.g., macular hole)~* Media opacity will not be an exclusion criterion provided that the investigator can assess the presence or absence of DME on OCT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Naval Medical Center San Diego (NMCSD) - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* previous upper or lower limb amputation including at least one metacarpal or metatarsal bone, respectively~* age 18 years or older~* phantom limb and/or stump pain described as at least a 2 on the NRS for the previous week \[and pain occurring on a weekly basis over the previous month\]~* willing to have an ambulatory perineural infusion for 6 days~* willing to avoid additional new analgesic interventions from 4 weeks prior to at least 4 weeks following catheter placement, and preferably to 6 months following catheter placement~* the availability of a caretaker who will transport the subject home following the procedure and remain with the subject for the first night of the infusion~Exclusion Criteria:~* known hepatic or renal insufficiency~* allergy to the study medications~* possessing a contraindication to perineural catheter placement or perineural local anesthetic infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): 3-7 days of perineural local anesthetic infusion
- Placebo (Type: PLACEBO_COMPARATOR): 3-7 days of perineural normal saline infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV mesothelioma that is unlikely to respond to existing therapy and for which no curative therapy exists~  * Evidence of disease by CT scan or MRI~PATIENT CHARACTERISTICS:~Age:~* 1 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~* Hepatic function adequate~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* Not at high medical or psychiatric risk~* No nonmalignant systemic disease~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (or less if multiple tumors) and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm: Experimental: Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues